Dopaminergic Neurotransmission in Patients with Schizophrenia in Relation to Positive and Negative Symptoms

被引:46
作者
Pogarell, O. [1 ]
Koch, W. [2 ]
Karch, S. [1 ]
Dehning, S. [1 ]
Mueller, N. [1 ]
Tatsch, K. [2 ,3 ]
Poepperl, G. [2 ,4 ]
Moeller, H. -J. [1 ]
机构
[1] Univ Munich, Dept Psychiat, D-80336 Munich, Germany
[2] Univ Munich, Dept Nucl Med, D-80336 Munich, Germany
[3] Municipal Hosp Karlsruhe Inc, Dept Nucl Med, Karlsruhe, Germany
[4] Katharinen Hosp, Dept Nucl Med, D-70174 Stuttgart, Germany
关键词
schizophrenia; dynamic systems disorder; dopamine; IBZM SPECT; amphetamine challenge; POSITRON-EMISSION-TOMOGRAPHY; STRIATAL DOPAMINE; PREFRONTAL CORTEX; WORKING-MEMORY; BASE-LINE; BRAIN; AMPHETAMINE; SPECT; TRANSMISSION; DISORDERS;
D O I
10.1055/s-0032-1306313
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Schizophrenia is a complex dynamic disorder comprising a wide range of neurobiological alterations including dopaminergic dysfunction. The aim of the study was to investigate dynamic changes of dopaminergic neurotransmission in patients with schizophrenia (n = 8, mean age 25.4 +/- 5.8 years) in early stages of the disorder, compared to healthy control subjects (n = 7, mean age 23.6 +/- 2.7 years). A dynamic IBZM SPECT protocol was used to assess the endogenous dopamine release following an amphetamine challenge. Subjects received a bolus activity of 175 MBq followed by a continuous infusion of 45 MBq/h [I-123]IBZM. SPECT scans were performed 2 h after bolus injection, and 1 h following the amphetamine challenge (0.3 mg/kg). Striatal IBZM binding to dopamine D2 receptors was assessed with a volume-of-interest (VOI) technique. The change in IBZM binding between pre- and post-challenge scans was used as a measure of endogenous dopamine release triggered by amphetamine. At baseline, patients showed higher mean striatal IBZM binding compared to controls (0.77 +/- 0.09 vs. 0.68 +/- 0.07, p = 0.07). There was a statistically significant difference in IBZM binding between patients, with a predominance of negative vs. positive symptoms (0.84 +/- 0.08 vs. 0.71 +/- 0.04. p < 0.05). Upon amphetamine challenge, mean IBZM binding decreased by about 4.9 +/- 7.6 % in controls (n=7) compared to a mean of 12.4 +/- 5.8 % in subjects with schizophrenia (p < 0.05). In patients, paranoid symptoms showed a significant negative correlation with IBZM baseline binding, whereas there was a trend towards positive correlation with the decrease of IBZM binding under challenge. Negative symptoms showed positive associations with baseline IBZM binding. The data are in line with previous reports and contribute to the notion of a dynamic instability of the dopaminergic system in patients with schizophrenia, taking into account the psychopathology with respect to positive or negative symptoms.
引用
收藏
页码:S36 / S41
页数:6
相关论文
共 47 条
  • [11] Interactions between monoamines, glutamate, and GABA in schizophrenia: New evidence
    Carlsson, A
    Waters, N
    Holm-Waters, S
    Tedroff, J
    Nilsson, M
    Carlsson, ML
    [J]. ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2001, 41 : 237 - 260
  • [13] DAVIS KL, 1991, AM J PSYCHIAT, V148, P1474
  • [14] The computational role of dopamine D1 receptors in working memory
    Durstewitz, D
    Seamans, JK
    [J]. NEURAL NETWORKS, 2002, 15 (4-6) : 561 - 572
  • [15] The Dual-State Theory of Prefrontal Cortex Dopamine Function with Relevance to Catechol-O-Methyltransferase Genotypes and Schizophrenia
    Durstewitz, Daniel
    Seamans, Jeremy K.
    [J]. BIOLOGICAL PSYCHIATRY, 2008, 64 (09) : 739 - 749
  • [16] Neurocomputational models of working memory
    Durstewitz, Daniel
    Seamans, Jeremy K.
    Sejnowski, Terrence J.
    [J]. NATURE NEUROSCIENCE, 2000, 3 (11) : 1184 - 1191
  • [17] Positron emission tomography and single photon emission CT molecular imaging in schizophrenia
    Erritzoe, D
    Talbot, P
    Frankle, WG
    Abi-Dargham, A
    [J]. NEUROIMAGING CLINICS OF NORTH AMERICA, 2003, 13 (04) : 817 - +
  • [18] Treatment of the symptoms of schizophrenia: a combined analysis of double-blind studies comparing risperidone with haloperidol and other antipsychotic agents
    Glick, ID
    Lemmens, P
    Vester-Blokland, E
    [J]. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2001, 16 (05) : 265 - 274
  • [19] Psychopharmacologic treatment strategies for depression, bipolar disorder, and schizophrenia
    Glick, ID
    Suppes, T
    DeBattista, C
    Hu, RJ
    Marder, S
    [J]. ANNALS OF INTERNAL MEDICINE, 2001, 134 (01) : 47 - 60
  • [20] KAY SR, 1987, PSYCHIAT DEV, V5, P79